Cellular immune system – no discrete molecular target

The designation 'Cellular immune system – no discrete molecular target' refers to therapeutic interventions that modulate immune function through broad cellular activation rather than by binding to a specific protein or receptor (StatPearls, 2023). This category is often used in pharmacological databases to classify agents like the BCG vaccine, which induces a local inflammatory response and recruits various immune cells to treat conditions such as bladder cancer (NCI, 2022). These treatments typically trigger a complex cascade involving multiple cell types, including macrophages, natural killer cells, and T-lymphocytes, to enhance the host's overall anti-tumor or anti-pathogen response.\n\nBecause these therapies lack a single molecular focal point, they are characterized by their systemic physiological effects and phenotypic outcomes in cell-based assays (ChEMBL, 2024). While effective, the absence of a discrete target complicates the prediction of off-target effects and systemic toxicities like cytokine release syndrome. Consequently, monitoring these therapies requires assessing global immune status and systemic biomarkers rather than specific molecular occupancy.

Other names

Non-specific immunomodulationCellular immunotherapyImmune system (unspecified target)Non-specific immune stimulation

Non-specific stimulation or modulation of immune cell populations, such as macrophages and T-cells, to elicit a systemic biological response rather than acting through a single molecular receptor (StatPearls, 2023).